{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:50:24Z","timestamp":1789775424084,"version":"4.0.1"},"reference-count":114,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:00:00Z","timestamp":1530144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","award":["AID-OAA-A-10-00068"],"award-info":[{"award-number":["AID-OAA-A-10-00068"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","award":["AID-OAA-A-14-00010"],"award-info":[{"award-number":["AID-OAA-A-14-00010"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","award":["GPO-A-00-08-00005-00"],"award-info":[{"award-number":["GPO-A-00-08-00005-00"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0199778","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T18:30:23Z","timestamp":1530210623000},"page":"e0199778","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":60,"title":["Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9826-6664","authenticated-orcid":true,"given":"Andrea Ries","family":"Thurman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill L.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Brache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith R.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelima","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Z.","family":"Stanczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene S.","family":"Dezzutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Hillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy C.","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raina","family":"Fichorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana N.","family":"Asin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Rollenhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo F.","family":"Doncel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,6,28]]},"reference":[{"key":"ref1","unstructured":"United Nations. Prevention Gap Report. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/wwwunaidsorg\/sites\/default\/files\/media_asset\/2016-prevention-gap-report_enpdf\" xlink:type=\"simple\">http:\/\/wwwunaidsorg\/sites\/default\/files\/media_asset\/2016-prevention-gap-report_enpdf<\/ext-link> [Internet]. 2016."},{"issue":"15","key":"ref2","first-page":"456","article-title":"Seroprevalence of herpes simplex virus type 2 among persons aged 14\u201349 years\u2014United States, 2005\u20132008","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"992","key":"ref3","first-page":"299","article-title":"Herpes simplex virus type 2: epidemiology and management options in developing countries","volume":"84","author":"G Paz-Bailey","year":"2008","journal-title":"Postgrad Med J"},{"issue":"1","key":"ref4","article-title":"Rates of Unintended Pregnancy Remain High In Developing Regions","volume":"37","author":"A Kott","year":"2011","journal-title":"International Perspectives on Sexual and Reproductive Health"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMsa1506575","article-title":"Declines in Unintended Pregnancy in the United States, 2008\u20132011","volume":"374","author":"LB Finer","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1728-4465.2010.00250.x","article-title":"Unintended pregnancy: worldwide levels, trends, and outcomes","volume":"41","author":"S Singh","year":"2010","journal-title":"Stud Fam Plann"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1056\/NEJMoa1410649","article-title":"Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection","volume":"373","author":"SS Abdool Karim","year":"2015","journal-title":"N Engl J Med"},{"issue":"5996","key":"ref8","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Q Abdool Karim","year":"2010","journal-title":"Science"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"JM Marrazzo","year":"2015","journal-title":"N Engl J Med"},{"key":"ref10","unstructured":"Rees H, Delany-Moretlwe S, Lombard C, Baron D, Panchia R, Myer L, et al. FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women. CROI 2015; Seattle, WA2015."},{"issue":"Suppl 1","key":"ref11","doi-asserted-by":"crossref","first-page":"A31","DOI":"10.1089\/aid.2014.5047a.abstract","article-title":"Association of Tenofovir [TFV] Detection with Reduced Risk of Herpes Simplex virus Type-2 [HSV-2] Acquisition in the VOICE [MTN 003] Study","volume":"30","author":"J Marrazzo","year":"2014","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref12","article-title":"Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women","author":"JM Baeten","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"ref13","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","article-title":"Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women","volume":"375","author":"A Nel","year":"2016","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"ref14","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.antiviral.2013.09.016","article-title":"Prioritizing multipurpose prevention technology development and investments using a target product profile","volume":"100","author":"J Romano","year":"2013","journal-title":"Antiviral Res"},{"issue":"Suppl 5","key":"ref15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1471-0528.12911","article-title":"Ensuring successful development and introduction of multipurpose prevention technologies through an innovative partnership approach","volume":"121","author":"B Young Holt","year":"2014","journal-title":"BJOG"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"e88509","DOI":"10.1371\/journal.pone.0088509","article-title":"Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy","volume":"9","author":"JT Clark","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"6272","DOI":"10.1128\/AAC.01431-12","article-title":"A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis","volume":"56","author":"TJ Johnson","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1742-1241.2003.tb10514.x","article-title":"Steroidal contraceptive vaginal rings","volume":"57","author":"NN Sarkar","year":"2003","journal-title":"Int J Clin Pract"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1089\/aid.2012.0271","article-title":"Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues","volume":"29","author":"N Chandra","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1128\/JCM.29.2.297-301.1991","article-title":"Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation","volume":"29","author":"RP Nugent","year":"1991","journal-title":"J Clin Microbiol"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1089\/aid.2015.0006","article-title":"Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity","volume":"31","author":"AR Thurman","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/aid.2015.0182","article-title":"Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks [HPTN 066]","volume":"32","author":"CW Hendrix","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/QAI.0000000000000110","article-title":"Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1","volume":"66","author":"BC Herold","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"e55013","DOI":"10.1371\/journal.pone.0055013","article-title":"MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments","volume":"8","author":"CW Hendrix","year":"2013","journal-title":"PLoS One"},{"key":"ref25","article-title":"Guidance for Industry: Bioanalytical Method Validation","year":"2001"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0010-7824(75)90088-8","article-title":"Radioimmunoassay of serum d-norgestrel in women following oral and intravaginal administration","volume":"12","author":"FZ Stanczyk","year":"1975","journal-title":"Contraception"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor [T-20] monotherapy","volume":"46","author":"X Wei","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/QAI.0000000000000897","article-title":"A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film","volume":"71","author":"KE Bunge","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"ref29","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/jac\/dks173","article-title":"Reformulated tenofovir gel for use as a dual compartment microbicide","volume":"67","author":"CS Dezzutti","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"e16475","DOI":"10.1371\/journal.pone.0016475","article-title":"A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel","volume":"6","author":"MJ Keller","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1089\/aid.2015.0264","article-title":"Comparison of Follicular and Luteal Phase Mucosal Markers of HIV Susceptibility in Healthy Women","volume":"32","author":"AR Thurman","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/mi.2011.34","article-title":"Enhanced HIV-1 replication in ex vivo ectocervical tissues from post-menopausal women correlates with increased inflammatory responses","volume":"4","author":"C Rollenhagen","year":"2011","journal-title":"Mucosal Immunol"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0015-0282(16)48436-0","article-title":"The prediction of ovulation: a comparison of the basal body temperature graph, cervical mucus score, and real-time pelvic ultrasonography","volume":"43","author":"A Leader","year":"1985","journal-title":"Fertil Steril"},{"issue":"5","key":"ref34","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0015-0282(16)59530-2","article-title":"Cervical mucus changes in relationship to urinary luteinizing hormone","volume":"48","author":"J Nulsen","year":"1987","journal-title":"Fertil Steril"},{"issue":"1","key":"ref35","first-page":"65","article-title":"Prediction and detection of ovulation: an evaluation of the cervical mucus score","volume":"22","author":"KA Abidogun","year":"1993","journal-title":"Afr J Med Med Sci"},{"issue":"6","key":"ref36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/j.1879-3479.1972.tb00857.x","article-title":"The Cervical Score: A Simple Semiquantitative Method for Monitoring of the Menstrual Cycle","volume":"10","author":"V Insler","year":"1972","journal-title":"International Journal of Gynaecology and Obstetrics"},{"key":"ref37","article-title":"The World Health Organization Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction","year":"1999"},{"issue":"3","key":"ref38","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0015-0282(16)49217-4","article-title":"A standardized approach for evaluating the penetration of human spermatozoa into cervical mucus in vitro","volume":"45","author":"IJ Pandya","year":"1986","journal-title":"Fertil Steril"},{"key":"ref39","unstructured":"SAS. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. I the USA and other countries. indicates USA registration. 2011;9.3."},{"key":"ref40","unstructured":"Division of AIDS. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/rsctech-rescom\/docs\/default-source\/safety\/daids_ae_grading_table_v2_nov2014pdf?sfvrsn=8\" xlink:type=\"simple\">http:\/\/rsctech-rescom\/docs\/default-source\/safety\/daids_ae_grading_table_v2_nov2014pdf?sfvrsn=8<\/ext-link> [Internet]. 2014."},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/QAI.0000000000000607","article-title":"Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness","volume":"69","author":"AD Kashuba","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9787","key":"ref42","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0140-6736(11)60878-7","article-title":"Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women","volume":"378","author":"SS Karim","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"ref43","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/JVI.05842-11","article-title":"Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue","volume":"86","author":"C Dobard","year":"2011","journal-title":"J Virol"},{"issue":"20","key":"ref44","doi-asserted-by":"crossref","first-page":"10358","DOI":"10.1128\/JVI.01073-09","article-title":"Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine","volume":"83","author":"UM Parikh","year":"2009","journal-title":"J Virol"},{"key":"ref45","unstructured":"Taneva E, Cameron S, Cheshenko N, Srinivasan S, Fredricks D, Herold BC. Modulation of Tenofovir Pharmacokinetics and Antiviral Activity by Vaginal Microbiota: Implications for Topical Preexposure Prophylaxis. HIV R4P; Chicago, IL, USA2016."},{"issue":"2","key":"ref46","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.contraception.2016.03.010","article-title":"The elusive minimum threshold concentration of levonorgestrel for contraceptive efficacy","volume":"94","author":"G Cherala","year":"2016","journal-title":"Contraception"},{"issue":"2","key":"ref47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0028-2243(93)90252-8","article-title":"Preliminary report of unexpected local reactions to a progestogen-releasing contraceptive vaginal ring","volume":"48","author":"W Bounds","year":"1993","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2","key":"ref48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0010-7824(00)00137-2","article-title":"A randomized comparison of the effects on vaginal and cervical epithelium of a placebo vaginal ring with non-use of a ring","volume":"62","author":"E Weisberg","year":"2000","journal-title":"Contraception"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"45725","DOI":"10.1038\/srep45725","article-title":"Tenofovir Inhibits Wound Healing of Epithelial Cells and Fibroblasts from the Upper and Lower Human Female Reproductive Tract","volume":"8","author":"M Rodriguez-Garcia","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"ref50","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/QAI.0000000000000824","article-title":"Exploring Genitoanal Injury and HIV Risk Among Women: Menstrual Phase, Hormonal Birth Control, and Injury Frequency and Prevalence","volume":"71","author":"BM Brawner","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref51","unstructured":"Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Pre-exposure Prophylaxsis for HIV in women: Daily Oral Tenofovir, Oral Tenofovir\/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study [MTN 003]. CROI 2013; Atlanta, GA2013."},{"issue":"15","key":"ref52","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1097\/00002030-200010200-00002","article-title":"The use of colposcopy in assessing vaginal irritation in research","volume":"14","author":"CK Mauck","year":"2000","journal-title":"AIDS"},{"key":"ref53","article-title":"Colposcopy: Still Useful in Microbicide Safety Trials?","author":"C Mauck","year":"2010","journal-title":"Microbicides"},{"issue":"Suppl 3","key":"ref54","first-page":"S184","article-title":"Guiding the vaginal microbicide trials with biomarkers of inflammation","volume":"37","author":"RN Fichorova","year":"2004","journal-title":"Journal of acquired immune deficiency syndromes"},{"issue":"4","key":"ref55","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1086\/322047","article-title":"The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission","volume":"184","author":"RN Fichorova","year":"2001","journal-title":"The Journal of infectious diseases"},{"issue":"3","key":"ref56","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1095\/biolreprod.104.029603","article-title":"Interleukin [IL]-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives","volume":"71","author":"RN Fichorova","year":"2004","journal-title":"Biology of reproduction"},{"issue":"5","key":"ref57","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/aid.2015.0088","article-title":"Biomarkers of Cervical Inflammation and Immunity Associated with Cervical Shedding of HIV-1","volume":"32","author":"C Mauck","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"ref58","doi-asserted-by":"crossref","first-page":"e00221","DOI":"10.1128\/mBio.00221-15","article-title":"The Contribution of Cervicovaginal Infections to the Immunomodulatory Effects of Hormonal Contraception","volume":"6","author":"RN Fichorova","year":"2015","journal-title":"mBio"},{"issue":"3 Suppl","key":"ref59","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1097\/OLQ.0b013e3181994191","article-title":"Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety","volume":"36","author":"JE Cummins Jr.","year":"2009","journal-title":"Sex Transm Dis"},{"key":"ref60","unstructured":"Keller MJ, Ray L, Atrio JM, Espinoza L, Sinclair S, Goymer J, et al. Early termination of a phase I trial of tenofovir disoproxil fumarate vaginal ring. CROI 2018; Boston, MA2018."},{"key":"ref61","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jpba.2016.08.022","article-title":"Stability behaviour of antiretroviral drugs and their combinations. 4: Characterization of degradation products of tenofovir alafenamide fumarate and comparison of its degradation and stability behaviour with tenofovir disoproxil fumarate","volume":"131","author":"VM Golla","year":"2016","journal-title":"J Pharm Biomed Anal"},{"issue":"116","key":"ref62","doi-asserted-by":"crossref","first-page":"96117","DOI":"10.1039\/C5RA17532A","article-title":"Stability behaviour of antiretroviral drugs and their combinations. 1: characterization of tenofovir disoproxil fumarate degradation products by mass spectrometry","volume":"5","author":"M Kurmi","year":"2015","journal-title":"RSC Advances"},{"issue":"10","key":"ref63","doi-asserted-by":"crossref","first-page":"e25974","DOI":"10.1371\/journal.pone.0025974","article-title":"A Multi-Compartment, Single and Multiple Dose Pharmacokinetic Study of the Vaginal Candidate Microbicide 1% Tenofovir Gel","volume":"6","author":"JL Schwartz","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"ref64","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/cid\/civ913","article-title":"Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel","volume":"62","author":"BC Herold","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"7","key":"ref65","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s10461-012-0248-4","article-title":"Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use","volume":"16","author":"ET Montgomery","year":"2012","journal-title":"AIDS Behav"},{"issue":"6","key":"ref66","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1089\/jwh.2007.0529","article-title":"An evaluation of intravaginal rings as a potential HIV prevention device in urban Kenya: behaviors and attitudes that might influence uptake within a high-risk population","volume":"17","author":"DJ Smith","year":"2008","journal-title":"J Womens Health [Larchmt]"},{"issue":"5","key":"ref67","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1089\/aid.2008.0184","article-title":"Safety and availability of dapivirine [TMC120] delivered from an intravaginal ring","volume":"25","author":"J Romano","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref68","article-title":"The effect of menopause on the innate antiviral activity of cervicovaginal lavage","author":"CA Chappell","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 1","key":"ref69","doi-asserted-by":"crossref","first-page":"A37","DOI":"10.1089\/aid.2014.5060.abstract","article-title":"Multicompartmental Pharmacokinetics of Tenofovir 1% Gel Using the BAT 24 Regimen Versus Daily and Single Pericoital Dosing","volume":"30","author":"JL Schwartz","year":"2014","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4","key":"ref70","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/aid.2016.0073","article-title":"Analytical Advances in the Ex Vivo Challenge Efficacy Assay","volume":"33","author":"N Richardson-Harman","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4","key":"ref71","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.chom.2011.08.015","article-title":"Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication","volume":"10","author":"G Andrei","year":"2011","journal-title":"Cell Host Microbe"},{"issue":"6341","key":"ref72","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.aai9383","article-title":"Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women","volume":"356","author":"NR Klatt","year":"2017","journal-title":"Science"},{"key":"ref73","unstructured":"Hillier S, Meyn L, Bunge K, Austin M, Moncla B, Dezzuitti CS, et al. Impact of vaginal microbiota on genital tissue and plasma concentrations of tenofovir. CROI 2017; Seattle, WA, USA2017."},{"issue":"8","key":"ref74","doi-asserted-by":"crossref","first-page":"e0134460","DOI":"10.1371\/journal.pone.0134460","article-title":"Effects of a One Year Reusable Contraceptive Vaginal Ring on Vaginal Microflora and the Risk of Vaginal Infection: An Open-Label Prospective Evaluation","volume":"10","author":"Y Huang","year":"2015","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"ref75","first-page":"4680","article-title":"Vaginal microbiome of reproductive-age women","volume":"108","author":"J Ravel","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1600-0897.2010.00964.x","article-title":"Increased COX-2 Expression in Human Vaginal Epithelial Cells Exposed to Nonoxynol-9, a Vaginal Contraceptive Microbicide that Failed to Protect Women from HIV-1 Infection","volume":"65","author":"IA Zalenskaya","year":"2011","journal-title":"Am J Reprod Immunol"},{"key":"ref77","unstructured":"Zalenskaya IA, Chandra N, Yousefieh N, Jackson SS, Anderson S, Mauck C, et al., editors. Use of Injectable Depot Medroxyprogesterone Acetate [DMPA] Downregulates Vaginal Epithelial Barrier Genes\u2014Similarly to Mucosal Inflammation. HIV R4P 2016; 2016; Chicago, IL, USA."},{"key":"ref78","article-title":"Mucosal effects of tenofovir 1% gel","volume":"4","author":"F Hladik","year":"2015","journal-title":"eLife"},{"issue":"10\u201311","key":"ref79","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1089\/aid.2015.0381","article-title":"Rectal 1% Tenofovir Gel Use Associates with Altered Epidermal Protein Expression","volume":"32","author":"L Romas","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"ref80","first-page":"105","article-title":"Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. I. Contraceptive efficacy and side effects. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation","volume":"41","author":"S Koetsawang","year":"1990","journal-title":"Contraception"},{"issue":"4","key":"ref81","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1023\/A:1006748626008","article-title":"Initial UK experience of the levonorgestrel-releasing contraceptive intravaginal ring","volume":"15","author":"J Sahota","year":"1999","journal-title":"Adv Contracept"},{"issue":"2","key":"ref82","first-page":"125","article-title":"Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. II. Expulsions and removals. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation","volume":"41","author":"S Koetsawang","year":"1990","journal-title":"Contraception"},{"issue":"6","key":"ref83","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/13625187.2012.713535","article-title":"The contraceptive vaginal ring, NuvaRing[[R]], a decade after its introduction","volume":"17","author":"FJ Roumen","year":"2012","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"ref84","unstructured":"World Contraceptive Use 20152015; <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.un.org\/en\/development\/desa\/population\/publications\/dataset\/contraception\/wcu2015.shtml\" xlink:type=\"simple\">http:\/\/www.un.org\/en\/development\/desa\/population\/publications\/dataset\/contraception\/wcu2015.shtml<\/ext-link>."},{"issue":"4","key":"ref85","first-page":"CD003552","article-title":"Skin patch and vaginal ring versus combined oral contraceptives for contraception","author":"LM Lopez","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"ref86","article-title":"Update on hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence, 2016","author":"CB Polis","year":"2016","journal-title":"AIDS"},{"issue":"2","key":"ref87","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/QAI.0000000000000103","article-title":"Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion","volume":"66","author":"C Morrison","year":"2014","journal-title":"Journal of acquired immune deficiency syndromes"},{"key":"ref88","article-title":"Depot Medroxyprogesterone Acetate Increases Immune Cell Numbers and Activation Markers in Human Vaginal Mucosal Tissues","author":"N Chandra","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5 Suppl","key":"ref89","first-page":"381","article-title":"Pharmacokinetics of depot medroxyprogesterone acetate contraception","volume":"41","author":"DR Mishell Jr","year":"1996","journal-title":"J Reprod Med"},{"issue":"2","key":"ref90","first-page":"129","article-title":"Risk of HIV Infection in Depot-Medroxyprogesterone Acetate [DMPA] Users: A Systematic Review and Meta-analysis","volume":"30","author":"J Brind","year":"2015","journal-title":"Issues in law & medicine"},{"issue":"2","key":"ref91","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.contraception.2014.02.006","article-title":"Effect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCs","volume":"90","author":"RP Huijbregts","year":"2014","journal-title":"Contraception"},{"issue":"8","key":"ref92","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s001980200080","article-title":"Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis","volume":"13","author":"Y Ishida","year":"2002","journal-title":"Osteoporos Int"},{"issue":"4","key":"ref93","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.contraception.2012.09.034","article-title":"Temporal changes in cervical mucus after insertion of the levonorgestrel-releasing intrauterine system","volume":"87","author":"MF Natavio","year":"2013","journal-title":"Contraception"},{"issue":"5","key":"ref94","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0010-7824(85)90016-2","article-title":"Pharmacokinetic and pharmacodynamic studies of vaginal rings releasing low-dose levonorgestrel","volume":"32","author":"BL Xiao","year":"1985","journal-title":"Contraception"},{"issue":"6","key":"ref95","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0010-7824(82)90132-9","article-title":"Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate","volume":"26","author":"BM Landgren","year":"1982","journal-title":"Contraception"},{"issue":"5","key":"ref96","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0010-7824(86)80006-3","article-title":"Pharmacokinetic studies with a vaginal delivery system releasing levonorgestrel at a near zero order rate for one year","volume":"33","author":"BM Landgren","year":"1986","journal-title":"Contraception"},{"issue":"2","key":"ref97","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0010-7824(81)90105-0","article-title":"Plasma levels of levonorgestrel in women during longterm use of norplant","volume":"23","author":"HB Croxatto","year":"1981","journal-title":"Contraception"},{"issue":"1","key":"ref98","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0010-7824(01)00226-8","article-title":"Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants","volume":"64","author":"I Sivin","year":"2001","journal-title":"Contraception"},{"issue":"3","key":"ref99","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0010-7824(87)90024-2","article-title":"Plasma levels of levonorgestrel and free levonorgestrel index in women using NORPLANT implants or two covered rods [NORPLANT-2]","volume":"35","author":"SE Olsson","year":"1987","journal-title":"Contraception"},{"issue":"5","key":"ref100","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00002018-200326050-00002","article-title":"Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants","volume":"26","author":"I Sivin","year":"2003","journal-title":"Drug Saf"},{"key":"ref101","unstructured":"Bayer Healthcare. Package Insert for Skyla Intrauterine System2000. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Skyla_PI.pdf\" xlink:type=\"simple\">http:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Skyla_PI.pdf<\/ext-link>."},{"key":"ref102","unstructured":"Bayer Healthcare. Package Insert Mirena Intrauterine System; <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Mirena_PI.pdf\" xlink:type=\"simple\">https:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Mirena_PI.pdf<\/ext-link>."},{"issue":"4","key":"ref103","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0039-128X(88)90170-5","article-title":"&quot;Free levonorgestrel index&quot; [FLI] is a better parameter than plasma level of levonorgestrel for predicting risk of pregnancy during use of subdermal contraceptive implants releasing levonorgestrel","volume":"52","author":"SE Olsson","year":"1988","journal-title":"Steroids"},{"issue":"4","key":"ref104","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0010-7824(98)00102-4","article-title":"Sex hormone binding globulin and free levonorgestrel index in the first week after insertion of Norplant implants","volume":"58","author":"F Alvarez","year":"1998","journal-title":"Contraception"},{"issue":"4","key":"ref105","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF02042590","article-title":"Free levonorgestrel index and its relationship with luteal activity during long-term use of Norplant implants","volume":"8","author":"V Brache","year":"1992","journal-title":"Adv Contracept"},{"issue":"1","key":"ref106","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.contraception.2016.08.001","article-title":"Effect of BMI and body weight on pregnancy rates with LNG as emergency contraception: analysis of four WHO HRP studies","volume":"95","author":"MP Festin","year":"2017","journal-title":"Contraception"},{"issue":"8","key":"ref107","first-page":"CD008452","article-title":"Hormonal contraceptives for contraception in overweight or obese women","author":"LM Lopez","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"ref108","first-page":"143","article-title":"Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. III. The relationship between pregnancy rate and body weight. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation","volume":"41","author":"S Koetsawang","year":"1990","journal-title":"Contraception"},{"issue":"2","key":"ref109","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0010-7824(94)90089-2","article-title":"Pharmacokinetic and pharmacodynamic effects of vaginal rings releasing levonorgestrel at a rate of 27 micrograms\/24 hours: a pilot study","volume":"49","author":"BM Landgren","year":"1994","journal-title":"Contraception"},{"issue":"6","key":"ref110","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0010-7824(85)80004-4","article-title":"A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel","volume":"32","author":"BM Landgren","year":"1985","journal-title":"Contraception"},{"issue":"1 Pt 2","key":"ref111","first-page":"461","article-title":"Intravaginal and intracervical devices for the delivery of fertility regulating agents","volume":"11","year":"1979","journal-title":"Journal of Steroid Biochemistry"},{"key":"ref112","unstructured":"Adedipe O, Jacot T, Thurman A, Doncel G, Clark M, editors. Can infrared spectroscopy [IR] coupled with chemometrics be used for objective measure of adherence to microbicide products? HIV R4P; 2014; Chicago, IL USA."},{"key":"ref113","unstructured":"Jacot T, Clark M, Adedipe O, Qiu J, Magana I, Godbout S, et al., editors. Clinical assessment of new objective measures of adherence for four placebo vaginal dosage platforms. HIV R4P; 2014; Chicago, IL USA."},{"key":"ref114","unstructured":"Thurman A, Caplena D, Clark M, Schwartz J, Littlefield S, Harris E, et al. Inspiring Demand: Leveraging Human Centered Design to Improve Microbicide Uptake and Adherence. HIV R4P; Chicago, IL, USA2016."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0199778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T12:02:57Z","timestamp":1693742577000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0199778"}},"subtitle":[],"editor":[{"given":"Alan","family":"Winston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,6,28]]},"references-count":114,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0199778","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,28]]}}}